SAB Biotherapeutics Inc (SABS)
3.15
-0.08
(-2.48%)
USD |
NASDAQ |
Jun 14, 16:00
3.15
0.00 (0.00%)
After-Hours: 20:00
SAB Biotherapeutics Enterprise Value: -14.15M for June 14, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 14, 2024 | -14.15M |
| June 13, 2024 | -13.41M |
| June 12, 2024 | -12.76M |
| June 11, 2024 | -11.93M |
| June 10, 2024 | -12.58M |
| June 07, 2024 | -16.05M |
| June 06, 2024 | -17.01M |
| June 05, 2024 | -18.02M |
| June 04, 2024 | -18.39M |
| June 03, 2024 | -18.58M |
| May 31, 2024 | -18.86M |
| May 30, 2024 | -18.86M |
| May 29, 2024 | -17.20M |
| May 28, 2024 | -18.12M |
| May 24, 2024 | -18.12M |
| May 23, 2024 | -19.32M |
| May 22, 2024 | -17.01M |
| May 21, 2024 | -16.36M |
| May 20, 2024 | -11.38M |
| May 17, 2024 | -9.719M |
| May 16, 2024 | -7.504M |
| May 15, 2024 | -6.304M |
| May 14, 2024 | -5.889M |
| May 13, 2024 | -5.474M |
| May 10, 2024 | -6.212M |
| Date | Value |
|---|---|
| May 09, 2024 | -6.304M |
| May 08, 2024 | -5.382M |
| May 07, 2024 | -5.474M |
| May 06, 2024 | -6.858M |
| May 03, 2024 | -6.028M |
| May 02, 2024 | -6.120M |
| May 01, 2024 | -5.382M |
| April 30, 2024 | -3.628M |
| April 29, 2024 | -4.551M |
| April 26, 2024 | -3.998M |
| April 25, 2024 | -6.212M |
| April 24, 2024 | -2.613M |
| April 23, 2024 | -2.982M |
| April 22, 2024 | -2.705M |
| April 19, 2024 | -3.628M |
| April 18, 2024 | -2.059M |
| April 17, 2024 | -0.7668M |
| April 16, 2024 | 1.817M |
| April 15, 2024 | -0.6745M |
| April 12, 2024 | -0.0746M |
| April 11, 2024 | -1.228M |
| April 10, 2024 | -1.228M |
| April 09, 2024 | -2.059M |
| April 08, 2024 | -2.059M |
| April 05, 2024 | -3.166M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-19.32M
Minimum
May 23 2024
487.99M
Maximum
Dec 01 2021
67.90M
Average
33.20M
Median
Apr 28 2023
Enterprise Value Benchmarks
| CEL-SCI Corp | 65.10M |
| AIM ImmunoTech Inc | 15.35M |
| IGC Pharma Inc | 25.36M |
| NovaBay Pharmaceuticals Inc | 3.382M |
| Protalix BioTherapeutics Inc | 55.51M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -5.026M |
| Total Expenses (Quarterly) | 11.39M |
| EPS Diluted (Quarterly) | -0.54 |
| Earnings Yield | -215.2% |